Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer
- PMID: 8861840
- DOI: 10.1007/BF01806676
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer
Abstract
We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinomas compared to non-tumoral glands. The cath-D RNA was located in mammary epithelial cancer cells rather than in fibroblasts, indicating that the cath-D gene was overexpressed in cancer cells, where the corresponding protein determined by immunohistochemical staining had been shown to be accumulated (E Roger et al., Human Pathol 25: 863-871,1994). In contrast strom-3 RNA in adjacent tissue sections used as a control of tissue localisation was mostly expressed in peritumoral fibroblasts rather than in cancer cells confirming previous results of Basset et al. and validating our methodology. UPA RNA was detected both in tumor cells and in stromal cells. In benign lesions the 3 protease RNAs were mostly found in epithelial cells. Stromal cells expressed UPA RNA in 5 of 7 lesions, cath-D and strom-3 in only one sample. We conclude that in breast cancer patients, cath-D gene expression is increased in epithelial mammary cancer cells at the RNA level as well as at the protein level, suggesting an altered transcriptional regulation. In non malignant lesions, the distribution was different with a predominant distribution in epithelial mammary cells for the 3 protease messenger RNA.
Similar articles
-
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z. Cancer. 1996. PMID: 8635127
-
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.Br J Cancer. 1991 Nov;64(5):926-32. doi: 10.1038/bjc.1991.428. Br J Cancer. 1991. PMID: 1931618 Free PMC article.
-
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.Breast Cancer Res Treat. 2000 May;61(1):1-12. doi: 10.1007/s10549-004-6659-9. Breast Cancer Res Treat. 2000. PMID: 10930085
-
Roles of the matrix metalloproteinases in mammary gland development and cancer.Breast Cancer Res Treat. 1998 Jul;50(2):97-116. doi: 10.1023/a:1006061115909. Breast Cancer Res Treat. 1998. PMID: 9822215 Review.
-
Urokinase-type plasminogen activator system and breast cancer (Review).Oncol Rep. 2005 Jul;14(1):105-12. Oncol Rep. 2005. PMID: 15944776 Review.
Cited by
-
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.Br J Cancer. 1998 May;77(10):1638-41. doi: 10.1038/bjc.1998.268. Br J Cancer. 1998. PMID: 9635840 Free PMC article.
-
[Optical imaging of fluorescence in the near infrared. From passive to enzymatically activated contrast medium].Radiologe. 2007 Jan;47(1):53-61. doi: 10.1007/s00117-006-1452-x. Radiologe. 2007. PMID: 17216511 Review. German.
-
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.BMC Cancer. 2006 Aug 31;6:216. doi: 10.1186/1471-2407-6-216. BMC Cancer. 2006. PMID: 16945123 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous